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have shorter parents and target height than SGA L+W+HC  chil-
dren.  Conclusions: Our study shows that subclassification of 
short SGA children might be a useful method for investigat-
ing SGA children as the subgroups revealed a different ges-
tation, delivery and postnatal growth pattern. Response to 
GH treatment was not different between the groups. 
 Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Small for gestational age (SGA) is the term used to de-
scribe a group of children born with a birth weight and/or 
birth length below the normal range of a reference popu-
lation, corrected for gestational age at birth. Since re-
duced size at birth may result from any number of fetal, 
maternal, placental or demographic influences, children 
born SGA comprise a heterogeneous group with a broad 
spectrum of clinical characteristics. While many chil-
dren born SGA achieve sufficient growth to normalize 
their stature by 2 years of age, approximately 10–15% 
maintain a height  ! –2 standard deviation scores (SDS) 
and continue to be short throughout adolescence and 
adulthood  [1] . Furthermore, in a population-based post-
natal growth study of 3,650 infants, of whom 8.1% were 
classified SGA according to their birth weight and birth 
length SDS, children born both short and light for gesta-
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 Abstract 
 Aim: We determined whether subclassification of short 
small for gestational age (SGA) children according to birth 
anthropometrics could delineate different patterns in gesta-
tion, delivery, postnatal growth, response to growth hor-
mone (GH) treatment and parental height.  Methods: 201 
short SGA children were divided into three groups, SGA L , 
SGA L+W  and SGA L+W+HC , according to birth length (L), weight 
(W) and head circumference (HC)  ^  –2.00 standard devia-
tion score (SDS).  Results: SGA L+W+HC  children were born after 
the shortest gestational age and more often by caesarean 
section than SGA L  children (36.3 vs. 38.1 weeks, 68.4 vs. 
24.4%). SGA L+W  children had an intermediate pattern and ex-
perienced most gestational hypertension (p = 0.01). At birth, 
SGA L+W+HC  children were shorter than SGA L  or SGA L+W  (–4.12 
vs. –2.67 and –3.72 SDS, p  ^  0.001). During the first 3 years 
of life, SGA L+W+HC  children exhibited an increased growth in 
height (0.98 SDS) and HC (1.28 SDS) than SGA L  (height, –0.06 
SDS; HC, –0.30 SDS) and SGA L+W  (height, 0.62 SDS; HC, –0.31 
SDS). However, HC SDS remained smaller for SGA L+W+HC  than 
the other groups at age 3. The groups did not differ in growth 
response during GH treatment. SGA L  children tended to 
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tional age were found to be shorter as adults than those 
born either short or light  [2] .
 Short SGA children appear to benefit from growth 
hormone (GH) treatment in terms of height increment. 
However, even after accounting for differences in paren-
tal height, age and duration of treatment, there appears 
to be a wide variation in the response to GH treatment 
that has been difficult to explain. The recent European 
approval of GH therapy to improve growth in short SGA 
children highlights the clinical relevance of ascertaining 
which short SGA children are most likely to benefit from 
treatment because potentially 23,000 European children 
meet the criteria for GH therapy annually  [1–3] .
 We have previously demonstrated that mean head cir-
cumference (HC) is significantly smaller (p  ! 0.001) in 
short SGA children with a reduced birth weight and birth 
length ( ^  –2.00 SDS) than in short SGA children born 
with merely a short birth length ( ^  –2.00 SDS)  [4] . The 
objective of this study was to determine whether subclas-
sification of short SGA children according to their birth 
anthropometrics could delineate differences in gestation, 
type of delivery, postnatal growth, response to GH treat-
ment and parental height.
 Methods 
 Patients 
 Data was evaluated of 201 SGA children with persistent short 
stature who were participating in prospective cohort trials evaluat-
ing the effect of GH treatment  [4–9] . SGA was defined as a birth 
length  ^  –2.00 SDS  [10] . Persistent short stature was defined as a 
height  ^  –2.00 SDS at the age  6 3 years  [11] . Children were divided 
into three groups based on anthropometrics at birth: group 1 com-
prised children with reduced birth length ( ^  –2.00 SDS) and nor-
mal birth weight and HC (SDS  1 –2.00) (SGA L ), group 2 comprised 
children with reduced birth length and weight ( ^  –2.00 SDS) and 
normal HC (SDS  1 –2.00) (SGA L+W ), and group 3 included children 
with reduced birth length, weight and HC (SDS  ^  –2.00) 
(SGA L+W+HC )  [10] . All children fulfilled the inclusion criteria of 
being Caucasian and having an uncomplicated postnatal period. 
Children with severe chronic illness or endocrine disorders, chro-
mosomal or genetic abnormalities, positive endomysial or trans-
glutaminase antibodies, skeletal disorders, psychosocial dwarfism, 
and growth failure caused by other syndromes (except Silver-Rus-
sell syndrome), were excluded from the study.
 The efficacy of 12 months GH treatment was evaluated in a 
subpopulation of 143 prepubertal children who were prepubertal 
at start and after 1 year of GH treatment. Prepuberty was defined 
as a bilateral testicular volume of  ^  3 ml for boys and Tanner stage 
M1 for girls. Children receiving medication for induction or post-
ponement of puberty were excluded from the analysis. The study 
protocol was approved by local Medical Ethics Committees and 
written informed consent was obtained from the parents/guard-
ians of each child.
 Clinical Parameters 
 Data regarding gestational age and birth measurements were 
retrieved from medical records of 201 children. Maternal medical 
records of 120 children were traced for the type of delivery. Data 
regarding gestational hypertension, smoking (by mother, father 
or both) and use of alcohol were retrieved by questionnaires. Post-
natal growth patterns from birth to 3 years of age were assessed 
using growth measurements from primary healthcare records, 
hospital records and baseline data from GH treatment studies of 
all 201 children. All measurements were plotted on a growth chart 
per child and checked for outliers to reduce within and between 
observer errors.
 Ponderal index was calculated by ((birth weight in grams/
birth length in cm 3 )  ! 100) and expressed as SDS  [12] . Body mass 
index (BMI) was calculated by (weight in kg/height in m 2 ) and 
SDS calculated according to Dutch reference values  [11] . A mea-
sure for birth head size compared to length was obtained by sub-
tracting birth head circumference SDS from birth length SDS. 
Height, weight, HC and sitting height were measured at start and 
after 1 year of GH treatment according to standardized methods 
 [4, 5] . Sitting height/standing height ratios for age were expressed 
as SDS using Dutch reference values  [12] .
 Parental heights of 160 mothers and 157 fathers were assessed 
using a Harpenden stadiometer and expressed as SDS using Dutch 
reference values  [13] . Target height (TH) SDS was calculated us-
ing Dutch reference values according to the formula: 1/2   (Height 
father + Height mother + 13) + 4.5 for boys and 1/2   (Height fa-
ther + Height mother – 13) + 4.5 for girls, where the addition of 
4.5 cm represents the secular trend  [11] . During GH treatment, 
biosynthetic GH was injected subcutaneously once daily at a dose 
of 1–2 mg/m 2  body surface area/day.
 Statistical Analysis 
 Anthropometric data were analyzed from birth until 3 years 
of age and before and after 12 months GH treatment. Analyses 
from birth to 3 years of age were performed on the total cohort of 
201 children by univariate analysis of variance (ANOVA). Abso-
lute birth size was adjusted for sex and gestational age to adjust 
for prematurity. Anthropometric SDS up to 3 years of age was also 
corrected for gestational age. The standard deviation (SD) of the 
adjusted means was approximated by SD = SE     n. The    2  test was 
used to analyze data on delivery and gestational factors.
 A subgroup analysis on the effect of GH treatment on growth 
was performed in a group of 143 prepubertal children. Analysis 
of the growth response was performed by using ANOVA. Baseline 
measurements were corrected for age at start of GH treatment, as 
covariate in ANOVA. The growth response during 12 months of 
GH treatment was adjusted for GH dose and age at start of GH 
treatment, also as covariate in ANOVA. Standard deviations of 
the adjusted means were approximated by SD = SE     n. Parental 
and target heights were compared by using ANOVA. Parental 
heights were compared to 0 SDS by one-sample t test.
 If an overall test comparing the three groups was significant 
(p  ^  0.05), post-hoc tests with Bonferroni correction were per-
formed. Statistical tests were performed using SPSS 11.0 Package 
(SPSS Inc., Chicago, Ill., USA).
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 Results 
 Birth Anthropometrics and Delivery 
 As shown in  table 1 , there were statistically signifi-
cant differences in anthropometric birth data between 
the SGA L,  SGA L+W  and SGA L+W+HC  children, with the 
latter being the most severely affected ones with regard 
to all anthropometric data ( table 1 ). Whereas SGA L+W+HC  
children were most proportional as expected, SGA L+W  
children were most disproportional with a low birth 
length SDS in combination with a spared head in the 
normal range. SGA L  children displayed an intermediate 
pattern. The type of delivery was different between 
groups. The majority (76%) of the SGA L  group was born 
after vaginal delivery in contrast to the SGA L+W  and 
SGA L+W+HC  children (46 and 32%,  table 1 ). Whereas the 
frequency of acute caesarean sections was not different 
between the groups, the frequency of elective caesarean 
sections was different. Within the SGA L+W+HC  group, 
53% of children were born after an elective caesarean 
section in contrast to 41% of the SGA L+W  and 13% of the 
SGA L  group.
 Gestational hypertension occurred most frequently
in the SGA L+W  children, in contrast with SGA L  and 
SGA L+W+HC  children (37.9 vs. 13.6 and 28.3%). Smoking 
during pregnancy was highly prevalent (49.7%) but did 
Table 1. Baseline characteristics of the total study population and the short SGA groups
Total SGAL SGAL+W SGAL+W+HC p value*
Sex boys/girls 109/92 36/31 35/35 38/26 0.55
GA weeks 36.883.5 38.183.1 36.083.7 36.383.7 0.0004a
Birth length cm 41.684.9 42.882.1 41.382.0 40.782.0 <0.000001a
SDS –3.5081.30 –2.6780.54 –3.7281.30 –4.1281.42 <0.00001a
Birth weight g 1,9218716 2,3478238 1,7628234 1,6498233 <0.000001c
SDS –2.4681.11 –1.2580.62 –2.8880.64 –3.2780.79 <0.000001c
Birth HC cm 31.583.0 32.481.2 32.481.2 29.781.2 <0.000001b
SDS –1.3481.45 –0.6480.88 –0.5981.11 –2.8980.98 <0.000001b
Birth HC-Birth length SDS 2.1681.71 2.0381.09 3.1381.89 1.2381.48 <0.000001c
Height mother cm 162.387.3 160.689.0 163.385.7 163.086.3 0.09
SDS –0.9781.17 –1.2481.45 –0.8080.93 –0.8581.01 0.09
Height father cm 176.586.9 176.287.7 175.486.9 178.485.7 0.07
SDS –0.8281.04 –0.8781.15 –0.9981.03 –0.5380.85 0.07
TH SDS –0.5180.86 –0.6680.86 –0.5280.87 –0.2980.83 0.12
Birth length-TH SDS –2.8981.59 –1.9581.12 –3.0781.38 –3.8181.74 <0.000001c
Height-TH SDS –2.6180.85 –2.5380.85 –2.6380.85 –2.7280.83 0.70
Type of delivery
Vaginal % (n) 52.5 (63) 75.6 (34) 45.9 (17) 31.6 (12) 0.0002c
GA (weeks) 38.9 (2.1) 39.1 (2.2) 38.6 (2.5) 38.6 (1.4) 0.66
Acute CS % (n) 13.3 (16) 11.1 (5) 13.5 (5) 15.8 (6) 0.82
GA (weeks) 37.1 (3.3) 35.8 (4.3) 37.4 (3.9) 37.8 (1.7) 0.61
Elective CS % (n) 34.2 (41) 13.3 (6) 40.5 (15) 52.6 (20) 0.001c
GA (weeks) 35.0 (2.8) 37.5 (2.1) 33.8 (2.3) 35.1 (2.9) 0.02d
Gestational factors
Hypertension % (n) 26.4 (43) 13.6 (8) 37.9 (22) 28.3 (13) 0.01d
Smoking % (n) 49.7 (42) 50.0 (25) 46.0 (23) 53.3 (24) 0.77
Alcohol % (n) 7.4 (12) 3.4 (2) 12.3 (7) 6.5 (3) 0.18
Values are means 8 SD unless indicated otherwise.
GA = Gestational age; HC = head circumference; TH = target height; CS = caesarean section; SDS = standard deviation score.
* Overall p value is presented by ANOVA for continuous and by 2 test for categorical variables.
Post-hoc testing showed: a SGAL differed in comparison to the SGAL+W and SGAL+W+HC groups; b SGAL+W+HC differed in com-
parison to the SGAL+W and SGAL groups; c All groups differed significantly from each other; d SGAL differed in comparison to the 
SGAL+W group. 
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differ between the groups. Alcohol use during gestation 
was reported in 7.4% of the total population and tended 
to be the most frequent in the SGA L+W  children, although 
not statistically different between the groups.
 Change in Height, Weight and HC during the First 
Three Years of Life 
 During the first 3 years of postnatal life, the extent of 
spontaneous growth differed between SGA L  children 
and children in the SGA L+W  and SGA L+W+HC  groups 
( fig. 1 ;  table 2 ). Growth in height was greatest for 
SGA L+W+HC  children. At birth, children in the SGA L+W+HC  
group were shorter than those in the other groups ( ta-
ble 1 ), but by 6 months of age they had attained a height 
SDS that was similar to SGA L+W  children (–3.21 SDS) al-
though they remained significantly shorter than SGA L  
children (–2.62 SDS; p = 0.001,  table 2 ). In contrast, the 
height SDS of SGA L  children remained virtually un-
changed during this period ( fig. 1 ).
 Whereas the SGA L  children had a substantial reduc-
tion in weight SDS from birth until the age of 3 years 
( fig. 2 ;  table 2 ), SGA L+W  and SGA L+W+HC  children main-
tained their weight SDS.
 At birth, HC was by definition significantly (p  ! 0.001) 
smaller in SGA L+W+HC  children than in the SGA L  and 
SGA L+W  children ( table 1 ). During the first 6 months of 
postnatal life there was a substantial increase in HC SDS 
in SGA L+W+HC  children from –2.9 SDS at birth to –1.9 
SDS at 6 months followed by a further, albeit slower in-
crease to –1.6 SDS at 3 years of age ( fig. 3 ;  table 2 ). Despite 
this marked increase, HC was at 3 years of age signifi-
cantly smaller (p  ! 0.001) in the SGA L+W+HC  children as 
compared to children in the other two groups. For chil-
dren born SGA L  or SGA L+W , HC decreased slightly dur-
ing the first 6 months of life and remained below their HC 
SDS at birth until the age of 3 years ( table 2 ).
 Ponderal index and BMI were investigated as mea-
sures for weight for height ratio at birth until the age of 3. 
SGA L  children had the highest ponderal index SDS at 
birth (3.86 SDS) in comparison with SGA L+W+HC  chil-
dren (0.17 SDS). SGA L+W  children showed an intermedi-
ate pattern (0.66 SDS). Although SGA L  children had the 
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 Fig. 1. Height (SDS) during the first 3 years of life and during 1 year of GH treatment for the short SGA groups. 
Data shown are means with standard errors. 
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highest ponderal index SDS at birth, they had a decrease 
in weight SDS, especially during the first 6 months, re-
sulting in a normal BMI SDS at age 3. From age 1 until 
age 3, SGA L+W  and SGA L+W+HC  children showed an in-
crease in BMI (0.16 vs. 0.29 SDS), whereas SGA L  children 
remained at the same SDS.
 Effect of GH Treatment on Height, Weight and HC 
 Mean age (6.8  8 2.3 years) at start of GH treatment 
was comparable between the SGA groups (p = 0.40,  ta-
ble 3 ). From 3 years of age until start of GH treatment, 
height SDS was maintained at a similar level within each 
group, and did not differ markedly between groups ( ta-
ble 3 ). GH treatment for 12 months resulted in a similar 
increase in height SDS (mean increase = 0.86 SDS) in all 
groups ( fig. 1 ). In all groups, height SDS after 12 months 
GH treatment was significantly (p  ! 0.001) higher than 
height SDS at start of treatment and was not different be-
tween groups (p = 0.35;  table 3 ).
 Between 3 years of age and start of GH treatment, 
weight SDS remained at approximately the same level in 
all groups ( fig. 2 ;  tables 2 ,  3 ), with SGA L  children remain-
ing at a weight SDS of approximately –2.5 SDS which was 
significantly higher than those in the other two groups 
Table 2. Spontaneous growth during the first 3 years of life in the total population and the three groups of short 
SGA children
Total SGAL SGAL+W SGAL+W+HC p value*
Height
0.0 year SDS –3.5081.30 –2.6780.54 –3.7281.30 –4.1281.42 <0.00001a
0.5 year SDS –3.0181.08 –2.6281.03 –3.2181.01 –3.2181.00 0.001a
1.0 year SDS –2.8380.84 –2.5580.83 –2.9680.81 –2.9880.81 0.004a
2.0 years SDS –2.9780.73 –2.8280.74 –2.9880.73 –3.1280.73 0.07
3.0 years SDS –3.0080.70 –2.8880.72 –3.0180.71 –3.1180.70 0.20
Change 0–3 SDS 0.5081.37 –0.0681.23 0.6281.15 0.9881.19 <0.00001a
Weight
0.0 year SDS –2.4681.11 –1.2580.62 –2.8880.64 –3.2780.79 <0.000001c
0.5 year SDS –2.7481.28 –2.0881.16 –2.9581.14 –3.2181.13 <0.00001a
1.0 year SDS –2.7581.14 –2.1481.07 –2.9481.05 –3.1981.05 <0.00001a
2.0 years SDS –2.7881.02 –2.2180.96 –2.9480.94 –3.2180.94 <0.00001a
3.0 years SDS –2.8280.96 –2.3480.92 –2.9680.91 –3.1980.90 0.00001a
Change 0–3 SDS –0.3681.10 –1.0480.98 –0.1080.99 0.0780.95 <0.00001a
HC
0.0 year SDS –1.3481.45 –0.6480.88 –0.5981.11 –2.8980.98 <0.000001b
0.5 year SDS –1.4080.94 –0.9880.84 –1.3180.83 –1.9180.83 <0.000001c
1.0 year SDS –1.2680.89 –0.9280.81 –1.1080.80 –1.7680.80 <0.00001b
2.0 years SDS –1.1580.87 –0.8680.82 –1.0480.81 –1.6080.81 <0.00001b
3.0 years SDS –1.1480.89 –0.8680.84 –1.0580.83 –1.5980.83 0.00002b
Change 0–3 SDS 0.1781.35 –0.3081.17 –0.3181.10 1.2881.16 <0.00001b
PI and BMI
0 year PI (SDS) 1.5783.31 3.8682.86 0.6682.84 0.1782.88 <0.00001a
1 year BMI (SDS) –1.2481.23 –0.5981.17 –1.4081.17 –1.7381.10 <0.00001a
3 years BMI (SDS) –1.0881.03 –0.5580.94 –1.2480.94 –1.4480.94 <0.00001a
Change BMI 1–3 BMI (SDS) 0.1780.81 0.0580.86 0.1680.86 0.2980.79 0.26
Values are means (SD) which, at age 0.5 until 3 years, were adjusted for gestational age.
HC = Head circumference; PI = ponderal index; BMI = body mass index; SDS = standard deviation score.
* Overall p value is presented of the SGA groups.
Post-hoc testing showed: a SGAL differed in comparison to the SGAL+W and SGAL+W+HC groups; b SGAL+W+HC 
differed in comparison to the SGAL+W and SGAL groups; c All groups differed significantly from each other.
 Ester  /Bannink  /van Dijk  /Willemsen  /
van der Kaay  /de Ridder  /Hokken-Koelega  
Horm Res 2008;69:89–9894
during this period ( tables 2, 3 ). GH treatment resulted in 
a significantly greater increment in weight SDS for the 
SGA L+W+HC  children than the SGA L  children (p = 0.02; 
 table 3 ).
 At start of GH treatment, HC SDS was significantly 
greater in SGA L  children than in SGA L+W  or SGA L+W+HC  
children (p = 0.002;  table 3 ;  fig. 3 ). GH treatment resulted 
in a similar increase in HC in all groups ( table 3 ). Despite 
this increase, HC remained the smallest for SGA L+W+HC  
and SGA L+W  children after 1 year of GH treatment at
–1.12 SDS and –0.88 SDS in comparison with the children 
in the SGA L  group, being –0.46 SDS (p = 0.001).
 At start of GH treatment, the sitting height to height 
ratio was not statistically significant between the groups, 
SGA L  children having a mean (SD) of 1.42 (1.63) SDS, 
SGA L+W  children 1.33 (1.22) SDS, and SGA L+W+HC  chil-
dren 1.51 (1.60) SDS (p = 0.86).
 Parental Height 
 Parental heights (mother and father) were not signifi-
cantly different between the SGA groups ( table 1 ). Paren-
tal height was lower than average (mother, –0.97 SDS; 
father, –0.82 SDS, in comparison to 0 SDS, both p  ! 
0.001). Although mean height SDS for mothers of SGA L  
children (–1.24 SDS) was lower than those of the other 
SGA groups, there was no statistical difference between 
the three groups (p = 0.09;  table 1 ). Target height (TH) 
SDS tended to be the lowest for SGA L  children (–0.66 
SDS) and the highest for SGA L+W+HC  children (–0.29 
SDS), SGA L+W  children showing an intermediate pattern 
at –0.52 SDS. Height SDS corrected for TH SDS was sig-
nificantly different at birth but not at start of GH treat-
ment (Birth length-TH, Height-TH SDS,  table 1 ). All 
groups had a height SDS far below their TH SDS ( ta-
ble 1 ).
 Discussion 
 The aim of this study was to determine in short SGA 
children whether differences in birth anthropometrics, 
with respect to length, weight, and HC, were associated 
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 Fig. 2. Weight (SDS) during the first 3 years of life and during 1 year of GH treatment for the short SGA groups. 
Data shown are means with standard errors. 
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with differences in gestation, type of delivery, postnatal 
growth, parental height, and response to GH treatment. 
Our results show that SGA L+W+HC  children experienced 
the most severe growth restriction during pregnancy. 
This is partly explained by their definition to have a 
length, weight and HC  ^  –2.00 SDS, but was often 1 until 
2 SDS below –2.00 SDS. SGA L+W  children showed an in-
termediate pattern with regard to birth length and weight 
in comparison with SGA L  and SGA L+W+HC  children. No-
tably, SGA L+W+HC  had the greatest increase in height and 
HC during early postnatal life, although at the age of 3, 
HC SDS and weight SDS still were significantly lower 
than those born SGA L . SGA subclassification could not 
predict a differential response to GH treatment as an in-
creased growth was seen for all three groups. After 1 year 
of treatment however, HC and weight of SGA L+W+HC  and 
SGA L+W  children remained significantly below those of 
SGA L  children.
 SGA L  children had no postnatal increase in growth, 
showed a marked decrease in weight and also a decline in 
HC SDS. In contrast, short SGA L+W  and SGA L+W+HC  chil-
dren had a significant increase in growth during early 
postnatal life. These differences in postnatal growth pat-
terns might result from different genetic and environ-
mental parameters influencing SGA L  children as com-
pared with the SGA L+W  and SGA L+W+HC  children. 
SGA L+W+HC  children suffered from severely impaired 
prenatal growth, but experienced a marked increase in 
growth after birth. In contrast, SGA L  children were most-
ly born after a vaginal delivery, were less small at birth 
and showed a decrease in growth in height and weight 
after birth. Also, parents of SGA L  children and especially 
their mothers, tended to be shorter than those of the oth-
er groups. These findings suggest that SGA L  children re-
semble a growth pattern as observed in children with id-
iopathic short stature (ISS) who are also mainly born af-
ter a vaginal delivery, have a decreased growth after birth 
and in many cases short parents. It might well be that 
subtle skeletal abnormalities play a role in some short 
SGA L  children instead of generalized fetal growth re-
striction, explaining the more frequent vaginal deliveries. 
For this group of SGA children it might be interesting to 
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 Fig. 3. Head circumference (SDS) during the first 3 years of life and during 1 year of GH treatment for the short 
SGA groups. Data shown are means with standard errors. 
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perform genetic research into genes involved in pre- and 
postnatal bone development.
 SGA L+W  children were characterized by their interme-
diate birth size, type of delivery, and postnatal growth 
pattern in comparison to the SGA L  and SGA L+W+HC  chil-
dren. These children also had the highest frequency of 
gestational hypertension which might explain their short 
gestational age during elective caesarean section and their 
spared birth HC. This observation might suggest that 
SGA L+W  children, in contrast to SGA L  and SGA L+W+HC  
children, might be a consequence of gestational hyper-
tension. A previous report also showed that the combina-
tion of low birth weight and height is most frequent after 
gestational hypertension  [14] , which confirms our obser-
vation. We however could not observe that SGA L+W  chil-
dren were more prone to have cardiovascular risk factors 
as a higher postnatal weight or BMI increase in compar-
ison to the other groups. Further long-term follow-up of 
SGA L+W  children is needed to identify a potential higher 
risk to cardiovascular risk factors.
 SGA L+W+HC  children were the smallest at birth, with 
regard to length, weight and HC. We expected to find a 
comparable or somewhat smaller birth length SDS than 
in the other children, as birth length SDS  ^  –2.00 was the 
major inclusion criterion for all children in the study co-
hort. However, we found that SGA L+W+HC  children had a 
considerably shorter birth length than SGA L  and SGA L+W  
children, despite of having the highest target height of the 
groups. Interestingly, SGA L+W+HC  children had the great-
est increase in growth parameters of all groups, indicat-
ing that SGA L+W+HC  children might have had the most 
severe fetal growth restraint which disappeared after 
birth. Postnatal growth of the children with the most se-
vere growth retardation might be explained by regression 
to the mean. However, if this growth would be due to re-
gression to the mean then we would have expected growth 
of all growth parameters in the SGA L+W+HC  children. As 
there was no growth in weight, we suspect that regression 
had only a limited effect.
 Of note was the finding that 68% of SGA L+W+HC  chil-
dren were delivered by caesarean section in contrast to 
SGA L  children of whom 76% were born after vaginal de-
livery. It is likely that the SGA L+W+HC  children experi-
enced growth retardation from early in pregnancy, also 
Table 3. Effect of GH treatment on growth parameters in the total population and in the short SGA groups
Total SGAL SGAL+W SGAL+W+HC p value*
Sex boys/girls 75/68 24/29 23/22 28/17 0.24
Age at start years 6.8182.29 7.1282.42 6.4982.28 6.7982.14 0.40
GH dose mg/m2/day 1.1180.29 1.1080.28 1.1380.31 1.0980.29 0.76
Height
Start1 SDS –3.0480.62 –3.0580.62 –3.1080.62 –2.9680.62 0.54
After 1 year2 SDS –2.1880.65 –2.2580.64 –2.2180.64 –2.0780.63 0.35
Changes during 1 year2 SDS 0.8680.36 0.8180.24 0.8980.24 0.8980.24 0.13
Weight
Start1 SDS –3.0080.92 –2.5980.85 –3.3280.85 –3.1880.85 0.00007a
After 1 year2 SDS –2.2280.87 –1.9280.84 –2.5080.84 –2.2980.84 0.003a
Changes during 1 year2 SDS 0.7880.43 0.6780.37 0.8280.37 0.8880.37 0.02b
HC
Start1 SDS –1.1180.88 –0.7780.85 –1.1980.85 –1.4380.85 0.002a
After 1 year2 SDS –0.8080.92 –0.4680.87 –0.8880.87 –1.1280.87 0.001a
Changes during 1 year2 SDS 0.3180.39 0.3080.36 0.3380.37 0.3180.36 0.91
Values are means (SD).
HC = Head circumference; SDS = standard deviation score.
* Overall p value is presented of the SGA groups.
Post-hoc testing showed: a SGAL differed in comparison to the SGAL+W and SGAL+W+HC groups; b the SGAL 
group differed from the SGAL+W+HC group.
1 Means are adjusted for age at start of GH treatment.
2 Means are adjusted for age at start of GH treatment and GH dose.
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affecting head growth. It might well be that the percent-
age of deliveries by elective caesarean section was high 
due to this severe growth retardation which is often seen 
in combination with reduced placental blood flow.
 Phenotypic variation is by definition determined by 
the interaction between genetic and environmental fac-
tors. Currently most genetic research in short SGA chil-
dren is focused on the role of the insulin-like growth fac-
tor-I (IGF-I), IGF-I receptor (IGF-IR) and GH receptor 
genes in determining size at birth  [15–21] . Of particular 
interest is the finding that patients with mutations in the 
IGF-I or IGF-IR genes also had a reduced HC and various 
degrees of mental retardation  [15, 17–19] . SGA L+W+HC  
children showed, however, a combination of severe pre-
natal growth restraint and remarkable postnatal growth 
in height and HC, which is not a characteristic of subjects 
with a deletion or mutation in the IGF-I or IGF-IR gene. 
For that reason, it is unlikely that SGA L+W+HC  children 
have major deletions in these genes but minor variants 
might play a role. Further research into gene-gene and 
gene-environment interactions is needed to elucidate the 
etiology of SGA L+W+HC .
 Evidence from several studies suggests that pre- and 
postnatal HC growth may influence cognitive function 
in SGA children  [22–24] . For example, SGA children 
with reduced HC ( ^  P10) at birth and at 9 months of age 
experienced widespread impairments in their verbal and 
nonverbal IQ ratings, phonological awareness skills, vi-
sual-motor integration skills, problem-solving abilities 
and literacy skills at age 7–9  [23] . Other studies have 
shown that SGA children with a reduced height and/or 
insufficient growth in HC and/or height had the highest 
risk for subnormal intellectual and psychological perfor-
mance  [22, 24, 25] . Hence identification of short SGA 
children with small HC SDS may be clinically relevant as 
it may help to identify children at particular risk for learn-
ing difficulties.
 In this study, we have specifically evaluated SGA chil-
dren with persistent short stature, in contrast to SGA 
catch-up children, having a height  ! –2.00 SDS at 3 years 
of age. As a first step in subphenotyping the heteroge-
neous SGA group, we have focused on short SGA chil-
dren as they receive endocrine care for their growth re-
tardation, often including GH treatment.
 In conclusion, our study suggests that SGA children 
with persistent short stature may be subclassified accord-
ing to their birth length, weight and HC. Subclassifica-
tion using these criteria may provide a useful framework 
to explore the mechanisms underlying differences in the 
extent of spontaneous postnatal growth that are observed 
in a population of short SGA children. Such a subclassi-
fication of short SGA children might also be useful for 
elucidating underlying genetic or environmental causes 
of SGA and future risk profiles with regard to adult dis-
eases. Where SGA L  children appeared to experience the 
least fetal growth retardation and postnatal height incre-
ment as within ISS children, SGA L+W  children were most 
affected by gestational hypertension which might suggest 
effects on cardiovascular risk profiles in later life. 
SGA L+W+HC  children were born with the lowest HC but 
experienced a major increase in HC growth postnatally. 
In this group of children, further studies might be di-
rected at specialized interventions such as remedial teach-
ing on cognition during early infancy as well as evaluat-
ing the effect of GH treatment at an earlier age.
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